Percutaneous Transluminal Coronary Angioplasty Drug Eluting Balloon DEB Catheters Sales

Percutaneous Transluminal Coronary Angioplasty Drug Eluting Balloon DEB Catheters Sales Market Outlook

The global market for Percutaneous Transluminal Coronary Angioplasty Drug Eluting Balloon (DEB) Catheters is projected to reach approximately USD 2.5 billion by 2035, experiencing a significant compound annual growth rate (CAGR) of around 7.2% during the forecast period from 2025 to 2035. This growth can be attributed to the increasing prevalence of coronary artery disease (CAD) worldwide, along with advancements in balloon catheter technologies that enhance the efficacy and safety of percutaneous coronary interventions. Furthermore, the rising geriatric population, which is more susceptible to cardiovascular ailments, contributes to the surge in demand for these medical devices. The market is also bolstered by rising healthcare expenditures and improvements in healthcare infrastructure, particularly in emerging economies. Additionally, growing awareness about minimally invasive procedures among healthcare professionals and patients alike is expected to drive the adoption of DEB Catheters.

Growth Factor of the Market

The growth of the Percutaneous Transluminal Coronary Angioplasty Drug Eluting Balloon Catheters market is significantly influenced by a variety of factors, including technological advancements, increased patient populations, and evolving healthcare policies favoring cardiovascular treatments. The development of advanced materials and coating techniques for DEB Catheters has led to improved performance and better clinical outcomes, further driving their adoption in interventional cardiology. Additionally, a rise in the prevalence of lifestyle-related diseases, leading to a higher incidence of coronary artery disorders, has necessitated the need for effective therapeutic options. Furthermore, the growing focus on enhancing patient outcomes through less invasive treatment modalities has prompted healthcare facilities to incorporate these devices as standard practice. The ongoing research and clinical studies validating the safety and efficacy of drug-eluting technologies also instill confidence among healthcare providers, providing a solid impetus for market growth.

Key Highlights of the Market

• Increasing prevalence of coronary artery disease driving demand for DEB Catheters.
• Technological advancements enhancing the safety and efficacy of balloon catheter procedures.
• Growing geriatric population more susceptible to cardiovascular conditions.
• Rising healthcare expenditures facilitating the adoption of advanced medical technologies.
• Increasing awareness and preference for minimally invasive surgical procedures.

By Product Type

Plain Balloon Catheters:

Plain balloon catheters serve as the most foundational technology in percutaneous transluminal coronary angioplasty. These catheters are used to dilate narrowed or obstructed arteries during angioplasty procedures. They work by inflating a balloon within the artery, which compresses the plaque against the arterial wall, thereby widening the vessel and restoring blood flow. While they have been widely used, their limitations in preventing restenosis have led to the development of more advanced devices, such as drug-eluting balloons. Nevertheless, plain balloon catheters retain a significant market share due to their cost-effectiveness and simplicity of use, especially in cases where advanced technologies are not necessary.

Cutting Balloon Catheters:

Cutting balloon catheters are designed for the treatment of complex lesions where traditional balloon angioplasty may not be effective. These catheters incorporate small blades that allow for precise cutting of plaque upon inflation, which facilitates better expansion of the artery. This technology is particularly useful for heavily calcified lesions or those with fibrous caps that resist dilation. The ability of cutting balloon catheters to achieve a more favorable outcome in challenging cases has led to their growing adoption in clinical practice, contributing to an increase in demand within the market.

Scoring Balloon Catheters:

Scoring balloon catheters are another innovative advancement in the field of interventional cardiology. These devices feature a series of longitudinal scoring elements on the balloon surface that create controlled incisions in the plaque upon inflation. This mechanism improves the efficacy of dilatation, particularly in lesions that are resistant to conventional balloon angioplasty. Scoring balloons provide a unique solution by offering a balance between the efficacy of cutting balloon technology and the less aggressive nature of plain balloons, making them ideal for a wider range of applications in treating arterial blockages.

Drug Coated Balloon Catheters:

Drug coated balloon catheters exemplify a significant evolution in angioplasty technology, merging the principles of balloon dilation with localized drug delivery. These catheters are coated with pharmaceutical agents that are released directly into the arterial wall during inflation, effectively reducing the risk of restenosis. The adoption of drug-coated balloons is on the rise due to their ability to minimize complications associated with traditional angioplasty methods. Clinicians favor these devices for their dual action—mechanical dilation combined with pharmacological intervention—resulting in improved long-term outcomes for patients with coronary artery disease.

Drug Eluting Balloon Catheters:

Drug eluting balloon catheters represent the cutting-edge of angioplasty technology, designed to provide targeted therapy to inhibit neointimal hyperplasia, a key factor in restenosis. These balloons are infused with drugs such as paclitaxel or sirolimus, which are released into the arterial wall during the procedure. The increased efficacy of drug eluting balloons has made them a preferred choice among cardiologists, particularly in high-risk patients. As clinical evidence continues to affirm their benefits in preventing restenosis and improving patient outcomes, the demand for drug eluting balloons is expected to rise significantly, positioning them as a leading product type in the DEB catheter market.

By Application

Hospitals:

Hospitals are the primary application segment for Percutaneous Transluminal Coronary Angioplasty Drug Eluting Balloon Catheters. These facilities provide comprehensive medical services, including advanced diagnostics and interventional cardiology. The availability of specialized healthcare professionals and cutting-edge medical equipment enables hospitals to perform complex procedures requiring DEB catheters. Additionally, the high patient volume and diverse case complexities encountered in hospitals necessitate the use of advanced catheter technologies, thereby driving market growth in this segment. Hospitals also benefit from established relationships with manufacturers, ensuring access to the latest innovations in DEB technology.

Specialty Clinics:

Specialty clinics focusing on cardiovascular health are increasingly utilizing drug eluting balloon catheters as part of their treatment protocols. These clinics offer more personalized care, often specializing in procedures that require a higher level of expertise in interventional cardiology. The growing trend towards outpatient care has led to an increase in the number of specialty clinics providing angioplasty services. The ability to deliver high-quality care in a less formal environment, combined with the convenience of outpatient procedures, enhances the appeal of specialty clinics for patients seeking treatment for coronary artery disease.

Ambulatory Surgical Centers:

Ambulatory surgical centers (ASCs) have emerged as significant players in the market for drug eluting balloon catheters, particularly due to their focus on outpatient procedures. These centers provide a cost-effective alternative to hospital care while offering the same level of quality and expertise. With advancements in minimally invasive techniques, ASCs can perform angioplasty procedures efficiently, allowing patients to return home the same day. The increasing shift towards outpatient care models, fueled by rising healthcare costs and patient preferences for convenience, positions ASCs as a growth segment in the DEB catheter market.

Others:

The 'Others' category encompasses various healthcare facilities and practices that utilize drug eluting balloon catheters. This includes research institutions, rehabilitation centers, and alternative healthcare providers. Although this segment may represent a smaller market share, it is essential to recognize the role of these facilities in expanding the reach of advanced cardiovascular treatments. These providers may engage in clinical trials or specialized treatments that highlight the versatility and effectiveness of DEB technology, contributing to increased awareness and adoption across diverse healthcare settings.

By Distribution Channel

Direct Sales:

Direct sales play a crucial role in the distribution of Percutaneous Transluminal Coronary Angioplasty Drug Eluting Balloon Catheters. Manufacturers often engage directly with hospitals, specialty clinics, and ambulatory surgical centers to provide their products. This approach allows for better control over pricing, product information dissemination, and customer support. Direct engagement enables manufacturers to build strong relationships with healthcare providers, ensuring they understand the specific needs and requirements of their clientele. Furthermore, direct sales facilitate quicker response times to market demands, providing a competitive advantage in an increasingly crowded landscape.

Distributor Sales:

Distributor sales represent another vital channel through which drug eluting balloon catheters are made available to healthcare facilities. Distributors serve as intermediaries between manufacturers and end-users, often having established networks that enhance access to various healthcare markets. This distribution model enables manufacturers to reach a broader audience and penetrate markets that may be difficult to access directly. Distributors often provide additional services such as inventory management, training for healthcare staff, and after-sales support, which can enhance the overall value proposition for end-users. This collaborative approach also allows manufacturers to focus on product development while leveraging the distribution expertise of their partners.

By Ingredient Type

Paclitaxel Eluting Balloons:

Paclitaxel eluting balloons are one of the most widely utilized types of drug eluting balloons in interventional cardiology. Paclitaxel, a chemotherapeutic agent known for its efficacy in inhibiting cell proliferation, is applied to the balloon surface, which releases the drug into the arterial wall during inflation. This localized delivery significantly reduces the risk of restenosis and improves long-term outcomes for patients. The growing body of clinical evidence supporting the effectiveness of paclitaxel eluting balloons has contributed to their widespread adoption, making them a prominent choice among healthcare providers for treating coronary artery disease.

Sirolimus Eluting Balloons:

Sirolimus eluting balloons utilize sirolimus, an immunosuppressant drug that has demonstrated efficacy in reducing neointimal hyperplasia. This ingredient's unique mechanism of action allows for effective prevention of restenosis, particularly in patients with complex vascular lesions. The adoption of sirolimus eluting balloons has increased due to their favorable safety profile and the growing body of clinical studies supporting their use. As healthcare providers seek advanced solutions to improve patient outcomes, sirolimus eluting balloons have gained traction in the market, contributing to the overall growth of drug eluting balloon catheters.

Zotarolimus Eluting Balloons:

Zotarolimus eluting balloons are emerging as a promising option in the field of drug eluting technologies. Zotarolimus is a potent drug that effectively inhibits smooth muscle cell proliferation, thereby reducing the likelihood of restenosis following angioplasty. The application of zotarolimus in balloon catheters has shown positive results in clinical trials, leading to an increased interest among interventional cardiologists. As the demand for effective treatment options continues to rise, zotarolimus eluting balloons are expected to play a pivotal role in the ongoing evolution of the DEB market.

Everolimus Eluting Balloons:

Everolimus eluting balloons utilize everolimus, an mTOR inhibitor, that has been effective in preventing restenosis in coronary arteries. This drug's mechanism of action allows for localized delivery directly to the vessel wall, ensuring minimal systemic exposure and maximizing therapeutic effects. The clinical experience with everolimus eluting balloons has demonstrated their efficacy in a range of patient populations, including those with high-risk lesions. As more clinical studies validate their benefits, everolimus eluting balloons are poised to become increasingly popular in the treatment of coronary artery disease.

Biolimus Eluting Balloons:

Biolimus eluting balloons represent an innovative approach in the drug eluting balloon segment. Biolimus is a biodegradable drug, which offers the advantage of reducing the risk of long-term drug exposure while effectively preventing restenosis. The use of biolimus in drug-eluting technology is gaining traction due to its favorable safety profile and efficacy. With an increasing emphasis on biocompatibility and reducing the burden of drug exposure on patients, biolimus eluting balloons are expected to witness a steady rise in adoption, contributing to the overall growth of the market for drug eluting balloon catheters.

By Region

The regional analysis of the Percutaneous Transluminal Coronary Angioplasty Drug Eluting Balloon Catheters market shows significant variation in market dynamics across different geographical areas. North America holds the largest market share, driven by advanced healthcare infrastructure, high prevalence of coronary artery diseases, and the presence of leading device manufacturers. The region is expected to experience a healthy growth rate, approximately 6.5% CAGR, over the forecast period due to rising healthcare expenditures and increasing adoption of minimally invasive procedures. Meanwhile, Europe also showcases robust market potential, supported by well-established healthcare systems and an increasing number of interventional cardiology procedures being performed annually. The growing emphasis on advanced therapeutic options is likely to enhance the market presence of DEB catheters in this region.

In contrast, the Asia Pacific region is anticipated to experience the highest growth rate, with an estimated CAGR of around 8.5% during the forecast period. This growth can be attributed to rising disposable incomes, increasing awareness of cardiovascular diseases, and expanding healthcare infrastructure in emerging economies like India and China. The expansion of healthcare services and the growing prevalence of lifestyle-related diseases further fuel demand for advanced medical devices, including DEB catheters. Latin America and the Middle East & Africa are gradually catching up, as improvements in healthcare access and rising investments in medical technology pave the way for the growth of the drug eluting balloon catheter market in these regions.

Opportunities

The market for Percutaneous Transluminal Coronary Angioplasty Drug Eluting Balloon Catheters is rife with opportunities that can be capitalized on by stakeholders. One such opportunity lies in the increasing focus on preventive healthcare measures and early diagnosis of cardiovascular diseases. As patients become more health-conscious and proactive about their cardiovascular health, the demand for effective and minimally invasive treatment options will increase. Healthcare providers are also looking to adopt advanced technologies that provide better outcomes, which can lead to the integration of DEB catheters into routine clinical practice. Additionally, companies that invest in R&D to innovate new formulations and improved delivery mechanisms for drug-eluting technologies can cater to the evolving needs of healthcare providers and patients alike.

Moreover, expansion into emerging markets presents a significant growth opportunity for players in the DEB catheter market. Increasing urbanization, a growing middle-class population, and the establishment of healthcare facilities in countries within Asia Pacific, Latin America, and the Middle East are driving demand for advanced medical devices. As these regions continue to invest in healthcare infrastructure, manufacturers have the opportunity to introduce their products to new customer bases, thereby increasing their market share. Partnerships with local distributors and healthcare institutions will be crucial in ensuring successful market penetration and product adoption in these burgeoning markets.

Threats

The Percutaneous Transluminal Coronary Angioplasty Drug Eluting Balloon Catheters market faces several threats that could hinder its growth trajectory. One of the most significant threats is the increasing level of competition, not only from established manufacturers but also from new entrants in the market. As more companies recognize the lucrative nature of the DEB catheter segment, price competition could intensify, potentially squeezing profit margins for manufacturers. Additionally, the rapid advancement of technology could render existing products obsolete, requiring continuous investment in R&D to keep up with emerging innovations. This fast-paced landscape demands constant vigilance from industry players to maintain relevance and market leadership.

Moreover, regulatory challenges can also pose a threat to the market's growth. Stringent regulatory scrutiny and lengthy approval processes for new medical devices can delay product launches, hindering market expansion efforts. In some regions, variability in regulatory requirements can create barriers to entry for manufacturers aspiring to global reach. The need for extensive clinical trials and validation can further complicate the journey to market, and companies may face significant financial burdens as a result. It is essential for key stakeholders to navigate these challenges effectively to ensure sustainable growth in the DEB catheter market.

Competitor Outlook

• Medtronic
• Boston Scientific Corporation
• Abbott Laboratories
• Johnson & Johnson (Cordis Corporation)
• B. Braun Melsungen AG
• Terumo Corporation
• Cardinal Health
• Cook Medical
• AngioDynamics
• Asahi Intecc Co., Ltd.
• Biotronik SE & Co. KG
• Medline Industries, Inc.
• Merit Medical Systems, Inc.
• W. L. Gore & Associates, Inc.
• STENTYS S.A.

The competitive landscape of the Percutaneous Transluminal Coronary Angioplasty Drug Eluting Balloon Catheters market is dynamic and characterized by the presence of several prominent players. These companies are engaged in continuous innovation, exploring new technologies and partnerships to enhance their offerings in the DEB catheter segment. Medtronic, for instance, remains a leader in the market, consistently investing in research and development to introduce advanced products that cater to evolving clinical needs. Their comprehensive portfolio and established market presence allow them to maintain a competitive edge over smaller players. Other major companies, such as Boston Scientific Corporation and Abbott Laboratories, have also established a strong foothold in the market through innovative product offerings and strategic collaborations with healthcare providers.

Furthermore, many manufacturers are shifting their focus towards expanding their geographical reach, particularly in emerging markets where the demand for advanced medical devices is on the rise. Companies like Terumo Corporation and Biotronik are capitalizing on growth opportunities in regions like Asia Pacific and Latin America to increase their market share. These companies often collaborate with local distributors and healthcare providers to better understand regional demands and tailor their offerings accordingly. Additionally, the growing trend towards strategic mergers and acquisitions enables these players to strengthen their market position and enhance their technological capabilities. For instance, acquisitions of smaller innovative firms by larger corporations can lead to the rapid integration of advanced technologies into existing product lines.

In summary, the competitive landscape of the Percutaneous Transluminal Coronary Angioplasty Drug Eluting Balloon Catheters market is characterized by a blend of established corporations and emerging innovators. Companies are increasingly focused on research and development, product innovation, and strategic collaborations to maintain their market position. By understanding the unique needs of patients and healthcare providers, these players are well-positioned to capture opportunities and navigate challenges within this vibrant market. The interplay between competition, technological advancement, and regulatory landscapes will continue to shape the future of DEB catheters, presenting both challenges and opportunities for stakeholders.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Medtronic
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Cook Medical
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 STENTYS S.A.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 AngioDynamics
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Cardinal Health
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Terumo Corporation
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Abbott Laboratories
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 B. Braun Melsungen AG
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Biotronik SE & Co. KG
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Asahi Intecc Co., Ltd.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Medline Industries, Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Merit Medical Systems, Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Boston Scientific Corporation
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 W. L. Gore & Associates, Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Johnson & Johnson (Cordis Corporation)
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Percutaneous Transluminal Coronary Angioplasty Drug Eluting Balloon DEB Catheters Sales Market, By Application
    • 6.1.1 Hospitals
    • 6.1.2 Specialty Clinics
    • 6.1.3 Ambulatory Surgical Centers
    • 6.1.4 Others
  • 6.2 Percutaneous Transluminal Coronary Angioplasty Drug Eluting Balloon DEB Catheters Sales Market, By Product Type
    • 6.2.1 Plain Balloon Catheters
    • 6.2.2 Cutting Balloon Catheters
    • 6.2.3 Scoring Balloon Catheters
    • 6.2.4 Drug Coated Balloon Catheters
    • 6.2.5 Drug Eluting Balloon Catheters
  • 6.3 Percutaneous Transluminal Coronary Angioplasty Drug Eluting Balloon DEB Catheters Sales Market, By Ingredient Type
    • 6.3.1 Paclitaxel Eluting Balloons
    • 6.3.2 Sirolimus Eluting Balloons
    • 6.3.3 Zotarolimus Eluting Balloons
    • 6.3.4 Everolimus Eluting Balloons
    • 6.3.5 Biolimus Eluting Balloons
  • 6.4 Percutaneous Transluminal Coronary Angioplasty Drug Eluting Balloon DEB Catheters Sales Market, By Distribution Channel
    • 6.4.1 Direct Sales
    • 6.4.2 Distributor Sales

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Percutaneous Transluminal Coronary Angioplasty Drug Eluting Balloon DEB Catheters Sales Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Percutaneous Transluminal Coronary Angioplasty Drug Eluting Balloon DEB Catheters Sales market is categorized based on

By Product Type

• Plain Balloon Catheters
• Cutting Balloon Catheters
• Scoring Balloon Catheters
• Drug Coated Balloon Catheters
• Drug Eluting Balloon Catheters

By Application

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Others

By Distribution Channel

• Direct Sales
• Distributor Sales

By Ingredient Type

• Paclitaxel Eluting Balloons
• Sirolimus Eluting Balloons
• Zotarolimus Eluting Balloons
• Everolimus Eluting Balloons
• Biolimus Eluting Balloons

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Medtronic
• Boston Scientific Corporation
• Abbott Laboratories
• Johnson & Johnson (Cordis Corporation)
• B. Braun Melsungen AG
• Terumo Corporation
• Cardinal Health
• Cook Medical
• AngioDynamics
• Asahi Intecc Co., Ltd.
• Biotronik SE & Co. KG
• Medline Industries, Inc.
• Merit Medical Systems, Inc.
• W. L. Gore & Associates, Inc.
• STENTYS S.A.